This review is carried out on the role of natriuretic peptides and attempts to use them properly, as a treatment, their functioning in the pathophysiology of heart failure with depressed systolic function was better understood. It is recounts its journey through multiple failed studies, explaining the reasons for its failures, until it achieved the desired success with the combination of sacubitril/valsartan. This produced a paradigm shift in the management of heart failure.

Heart failure with recovered ejection fraction is defined as the improvement of left ventricular systolic function (LVEF) to values ≥ 40%, after having presented a reduced LVEF (< 40%) at a previous time and ≥10% absolute improvement in LVEF. It is a chronic and dynamic condition with a high risk of relapse and deterioration, so close monitoring and optimal medical therapy are essential for its management. A case is presented of a young male patient with dilated cardiomyopathy with severe left ventricular systolic dysfunction, who with neurohormonal therapy for heart failure, showed rapid clinical recovery and improvement of ejection fraction and left ventricular remodeling. Further studies are needed to better understand this condition and its long-term treatment.